Clinical Trials in Bremen, Germany
2 recruiting
Showing 1–12 of 12 trials
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Breast Neoplasms
Novartis Pharmaceuticals3,250 enrolled267 locationsNCT06830720
Recruiting
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Breast CancerBreast NeoplasmsNeoplasm Metastasis
AstraZeneca800 enrolled107 locationsNCT05573893
Recruiting
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Female Breast Cancer
West German Study Group1,470 enrolled71 locationsNCT05792150
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences1,514 enrolled288 locationsNCT05633654
Recruiting
Phase 3
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
West German Study Group348 enrolled42 locationsNCT06081244
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
Pleural Mesothelioma
NovoCure Ltd.198 enrolled23 locationsNCT05538806
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364
Recruiting
Phase 4
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
Hormone Receptor-positive Metastatic Breast CancerHER2-negative Metastatic Breast Cancer
Prof. Wolfgang Janni300 enrolled54 locationsNCT05362760
Recruiting
Phase 2
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest120 enrolled13 locationsNCT06207734
Recruiting
Phase 2
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
GBG Forschungs GmbH120 enrolled25 locationsNCT06607757
Recruiting
Phase 4
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
Breast CancerBreast Cancer FemaleBreast Neoplasms+2 more
Institut fuer Frauengesundheit1,000 enrolled52 locationsNCT05452213